Loading
Loading
Research Overview
Synthetic amylin analogue with three proline substitutions preventing aggregation; slows gastric emptying, suppresses postprandial glucagon, and activates AMY1-3 receptors in brainstem to promote satiety — complementing mealtime insulin action.
Overview
Amylin is co-secreted with insulin by pancreatic beta cells in response to meals. Its physiological roles include slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety. Type 1 diabetes patients are amylin-deficient (beta cell destruction) and many type 2 patients have impaired amylin secretion, contributing to postprandial glucose dysregulation.
Pramlintide is a synthetic analogue incorporating three proline substitutions that prevent the aggregation characteristic of native amylin, enabling formulation and subcutaneous injection. It is administered before meals as part of insulin therapy to address the amylin component of postprandial glucose control — reducing glucagon, slowing gastric emptying, and promoting post-meal satiety.
The critical safety consideration with pramlintide is the interaction with concurrent insulin: pramlintide reduces postprandial glucose, meaning mealtime insulin doses typically require reduction (30–50%) to prevent hypoglycaemia when pramlintide is initiated. This adjustment represents the primary complexity of pramlintide use in clinical practice.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pramlintide (symlin) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Synthetic amylin analogue with three proline substitutions preventing aggregation; slows gastric emptying, suppresses postprandial glucagon, and activates AMY1-3 receptors in brainstem to promote satiety — complementing mealtime insulin action.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.